Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data may reveal best Second-Line therapy for multiple myeloma

NCT ID NCT07689006

Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks back at medical records of over 300 adults with relapsed/refractory multiple myeloma to compare how well different drug combinations work in everyday practice. Researchers are analyzing outcomes like how long patients live without their cancer worsening and overall survival for those who received pomalidomide-based treatments versus other standard therapies. The goal is to see which approach may offer better results after initial treatments stop working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pomalidomide (in combination with other drugs)
What this could lead to
If pomalidomide-containing regimens show better outcomes, this could help doctors choose more effective treatments for patients with relapsed/refractory multiple myeloma.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences. It does not prove one treatment is better than another.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

341 people

The number who actually took part.

Started

Dec 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with relapsed/refractory multiple myeloma treated in the OneOncology United States database who previously received both a lenalidomide-containing regimen and a proteasome inhibitor and subsequently initiated specified pomalidomide-containing or non-pomalidomide-containing regimens in the second-line or third-line setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of multiple myeloma (ICD-9: 203.00; ICD-10: C90.0x, C90) * Are ≥18 years of age at the index date * Have received a lenalidomide-containing regimen and received a proteasome inhibitor; exposures do not need to occur within the same line of therapy * Have received ≥1 subsequent lines of therapy after lenalidomide and proteasome inhibitor exposure * Have received one of the following treatment regimens as the subsequent line (index line) after lenalidomide and proteasome inhibitor exposure: * Pomalidomide-containing regimens: * Daratumumab, pomalidomide, and dexamethasone (DPd) * Carfilzomib, pomalidomide, and dexamethasone (KPd) * Non-pomalidomide-containing regimens: * Daratumumab, lenalidomide, and dexamethasone (DRd; lenalidomide-refractory participants only) * Daratumumab, bortezomib, and dexamethasone (DVd) * Daratumumab, carfilzomib, and dexamethasone (DKd) Exclusion Criteria: * Have \<6 months of follow-up from the index date; participants who died will be included even with \<6 months follow-up, but participants who died within 1 month after the index date will be excluded * Have \<6 months pre-index enrollment * Have other primary cancer diagnoses within 1 year pre-index * Excluded ICD-10 diagnosis codes: C00.xx-C76.xx, C7A, C80.xx-C88.xx, C91.xx-C96.xx, D00.xx-D09.xx, D37.xx-D47.1x, D47.3x-D49.xx * Excluded ICD-9 diagnosis codes: 149.x through 239.x * ICD codes 209.4, 209.5, 209.6, 209.7, D47.Z1, D47.Z2, and D3A will not be excluded * Received chimeric antigen receptor T-cell therapy or bispecific antibody therapy before index date or as the index line * Have ever enrolled in a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed/refractory multiple myeloma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed/refractory multiple myeloma

Contacts and locations

Locations

  • OneOncology Network

    Nashville, Tennessee, 37219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.